Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY26 Earnings Presentation
37 slides from Jubilant Ingrevia's earnings presentation, Oct 28, 2025
Slide 1: Exchange filing cover letter for press release and presentation
October 27, 2025 BSE Limited National Stock Exchange of India Limited Floor 25, P.J. Tower Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E) Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Press Release and presentation on the financials and opera
Slide 2: Investor Presentation October 2025
Investor Presentation October 2025 Innovating for a Sustainable Future 1
Slide 3: Forward-looking statements and notes
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 4: Management commentary on second quarter results
“We are pleased to share the financial results for the second quarter of this fiscal year. Our Speciality Chemicals segment continues to drive the growth momentum with double digit YoY revenue growth and a positive growth over last quarter. Our Nutrition business maintained a steady volume growth tr
Slide 5: Business Update
Business Update: The Specialty Chemicals segment continued on its revenue growth trajectory and reported 25%+ margins during the quarter, driven primarily by strong performance in Fine Chemicals and CDMO sales. We successfully delivered volumes against one of our new Agro CDMO innovator contract in
Slide 6: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Q2’FY26 Highlights 1 9 Business Segments Update 5
Slide 7: Company Overview
WV J UBILANT INGREVIA Company Overview. ° hh ds)
Slide 8: Transformation into Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 9: Business segments and global positions
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 10: Revenue mix by segment and geography
Consumer ROW Nutrition 5% 11% & Health Agro North Solutions 22% Pharma America 8% 17% Specialty 32% India Chemicals 57% 45% Europe Chemical Industrial 24% Intermediates 20% 39% Nutrition 22% 9
Slide 11: Facilities, people, products and customers
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 12: R&D Centers, Scientists, PhDs
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 ~150 ~30 R&D Centers Scientists PhDs 11
Slide 13: Business Leaders
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola President, Chief Preside
Slide 14: Q2 Highlights
Ww a ° at UBILANT —_" J INGREVIA + vas “en 8A ww . Q2’FY25 Highlights -
Slide 15: Market update: Pharma, Agrochem, Nutrition
PHARMA • Volumes remained steady across segments, especially in our core products in Fine Chemicals • Prices remained stable in most segments; Customers await clarity on tariff situation thus delaying decisions in a few opportunities • Paracetamol segment volumes witnessed moderate growth, with all
Slide 16: Business, Customer and Operations/ESG highlights
Business Customer Operations / ESG • Overall: Highest Quarterly Revenue, Sales • KAM: Opportunity funnel expansion to • Green power impact showing up: volume in last 10 quarters 100+ (70 in Q1) Power & Fuel expense dropped 16% • Acetyls: Highest revenue and volumes in • Confirmed: 10+ molecules in l
Slide 17: Q2 FY26 financial summary
1 Particulars Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Total Revenue 1,045 1,038 1,121 8% 7% 2,070 2,159 4% Total EBITDA 135 153 146 -5% 8% 254 300 18% EBITDA Margin (%) 13% 15% 13% 12% 14% Profit After Tax 59 75 70 -7% 18% 108 145 34% Profit After Tax Margin (%) 6% 7% 6% 5% 7% Basi
Slide 18: Segment-wise EBITDA Share
Segment-wise EBITDA Share (%) 6% 13% 10% 12% 25% 27% 17% 36% 36% 14% 13% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 76% 75% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Specialty
Slide 19: Segment EBITDA comparison
Specialty Chemicals Nutrition Chemical Intermediates EBITDA (Rs Cr.) EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 44% Y.o.Y De-Growth -13% Y.o.Y Growth -51% Q.o.Q De-Growth -4% Q.o.Q De-Growth -15% Q.o.Q Growth 18% 130 40 125 24 25 21 87 20 27% 26% 14% 17 13% 20% 12% 9% 4% 4% Q2 FY25 Q1 FY26 Q2 FY26
Slide 20: Business Segments Overview
Business Segments Overview 19
Slide 21: Specialty Chemicals: Pharma, Agrochemical, CDMO/FC
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Pharma End-use demand continued to show positive momentum, improvement witnessed Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y on YoY and QoQ basis Segment Revenue 433 478 485 1% 12% 864 963 11% Pharma - Pricing remained stable and
Slide 22: Nutrition: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Market demand remained steady with Q1 roll-over orders creating marginal uptick 1 Particulars Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y - Competition volume push weighed on Segment Revenue 182 179 181 1% -1% 368 359 Feed B3 -2% global prices
Slide 23: Chemical Intermediates: Volumes, Cost, Price
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Increase in India market volumes with marginal uptick in agro and paracetamol Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Segment Revenue 430 381 455 20% 6% 838 836 0% - Continued market challenges in Europe, Volumes driven by wea
Slide 24: Annexures
w eee ar Devene lA
Slide 25: Income statement
Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 QoQ YoY H1'FY25 H1'FY26 YoY Revenue from operations a) Sales/Income from operations 1029 1029 1110 8% 8% 2039 2139 5% b) Other operating income 16 9 11 30% -32% 30 20 -35% Total revenue from operations 1045 1038 1121 8% 7% 2070 2159 4% Other income 10 11 11 -4% 3
Slide 26: Segment revenue and EBITDA summary
Particulars1 Q2'FY25 Q1'FY25 Q2'FY25 QoQ (%) YoY (%) H1'FY25 H1'FY26 YoY (%) Total Revenue from Operations 1,045 1,038 1,121 8% 7% 2,070 2,159 4% Speciality Chemicals 433 478 485 1% 12% 864 963 11% Nutrition & Health Solutions 182 179 181 1% (1%) 368 359 (2%) Chemical Intermediates 430 381 455 20% 6
Slide 27: Debt position
Particulars1 30-Sep-24 31-Mar-25 30-Sep-25 Long Term Borrowings 450 453 458 Short Term Borrowings 263 303 336 Total Gross Debt 713 756 794 Cash & Equivalent 63 98 47 Total Net Debt 650 658 748 YoY change 15% • The capex for the quarter was Rs 59 Crore, which was primarily utilized towards the upcomi
Slide 28: Earnings call details
Date : October 27th, 2025 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on th
Slide 29: Thank you for your time
Jubilant Ingrevia Limited is a leading player in Specialty Chemicals For Investors: globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ Pavleen Taneja products and customized solutions that are innovative, cost-effective
Slide 30: Press Release: Q2 FY26 Results
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Monday, October 27th, 2025 JUBILANT INGREVIA LIMITED – Q2’FY26 RESULTS Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Total Revenue 1,045 1,038
Slide 31: Future Outlook
Future Outlook: Looking ahead to H2’FY26, we expect continued growth momentum, fueled by progress in our Specialty Chemicals and Nutrition businesses, along with an expected part-recovery in the Acetyls portfolio. We're also on track to start serving our major CDMO order in early 2026, a milestone t
Slide 32: Progress across our 5 pillars
portfolio, with multiple new queries and orders originating from Europe, underscoring our expanding global reach. 4) In the Chemical Intermediates segment, our strategic initiatives on Ethyl Acetate and Acetic Anhydride sales drove a notable QoQ and YoY growth in volumes and revenue, clocking highes
Slide 33: Segment Wise Analysis: Specialty Chemicals
Q2’FY26 Highlights | Segment Wise Analysis A. Specialty Chemicals Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Segment Revenue 433 478 485 1% 12% 864 963 11% % Share of Overall Revenue 41% 46% 43% 42% 45% EBITDA 87 130 125 -4% 44% 172 255 48% % EBITDA Margin 20% 27% 26% 20%
Slide 34: Nutrition and Chemical Intermediates segments
Food & Cosmetic B3 - Cosmetic-grade demand grew steadily on both QoQ and YoY basis - Prices for both food-grade and cosmetic-grade products remained stable Choline - Q2 typically sees lower volumes due to festivals, but showed steady YoY growth. - EU queries rose after anti-dumping duties on China;
Slide 35: Income Statement and Segment P&L
3. Income Statement – Q2’FY26 1 Particulars Q2'FY25 Q1'FY26 Q2'FY26 QoQ YoY H1'FY25 H1'FY26 YoY Revenue from operations a) Sales/Income from operations 1029 1029 1110 8% 8% 2039 2139 5% b) Other operating income 16 9 11 30% -32% 30 20 -35% Total revenue from operations 1045 1038 1121 8% 7% 2070 2159
Slide 36: Debt Position as on 30th September, 2025
5. Debt Position as on 30th September, 2025 Particulars1 30-Sep-24 31-Mar-25 30-Sep-25 Long Term Borrowings 450 453 458 Short Term Borrowings 263 303 336 Total Gross Debt 713 756 794 Cash & Equivalent 63 98 47 Total Net Debt 650 658 748 YoY change 15% All figures are in Rs Crore unless otherwise sta
Slide 37: For more information, please contact
For more information, please contact: For Investors Pavleen Taneja Siddharth Rangnekar Jubilant Ingrevia Limited CDR India Ph: +91-120 436 1000 Ph: +91 22 6645 1209 E-mail: pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com For Media Sandipan Ghatak Sahir Seth Ph: +919810776182 M: +91 999927011